Get the Stockscreener App
113.73
0.50%
0.6922
Monopar Therapeutics Inc stock is traded at $113.73, with a volume of 136.04K.
It is up +0.50% in the last 24 hours and up +2.24% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
See More
Previous Close:
$113.04
Open:
$113.35
24h Volume:
136.04K
Relative Volume:
0.62
Market Cap:
$763.17M
Revenue:
-
Net Income/Loss:
$-14.99M
P/E Ratio:
-55.04
EPS:
-2.0665
Net Cash Flow:
$-10.01M
1W Performance:
-2.35%
1M Performance:
+2.24%
6M Performance:
+109.55%
1Y Performance:
+218.15%
1-Day Range:
$111.60
$117.00
1-Week Range:
$107.78
$117.46
52-Week Range:
$29.18
$124.82
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
113.70 | 758.74M | 0 | -14.99M | -10.01M | -2.0665 |
VRTX
Vertex Pharmaceuticals Inc
|
515.31 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.34 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.59 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.54 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.30 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Morgan Stanley | Overweight |
| Nov-14-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-25 | Initiated | Leerink Partners | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
(MNPR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Monopar Therapeutics (NASDAQ:MNPR) Cut to Sell at Wall Street Zen - MarketBeat
Zacks Research Downgrades Monopar Therapeutics (NASDAQ:MNPR) to Hold - MarketBeat
Equities Analysts Offer Predictions for MNPR FY2029 Earnings - MarketBeat
Buy Rating Reiterated on Monopar as ALXN-1840 Advances in Wilson Disease; $125 Price Target Maintained - TipRanks
Monopar Therapeutics Shares Drop After Downgrade From Cantor Fitzgerald - marketscreener.com
Monopar downgraded to Neutral at Cantor (MNPR:NASDAQ) - Seeking Alpha
This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday - Benzinga
MNPR Maintained by Barclays -- Price Target Raised to $128.00 - GuruFocus
MNPR Downgraded by Cantor Fitzgerald -- Price Target Raised to $119 - GuruFocus
Monopar Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Cantor downgrades Monopar stock on valuation after 90% rally - Investing.com
Cantor downgrades Monopar stock on valuation after 90% rally By Investing.com - Investing.com Canada
Boris Peaker Maintains Buy Rating on Monopar, Reaffirming Unchanged $130 Price Target on ALXN1840’s Strong Clinical and Regulatory Profile - TipRanks
Saturn V Capital shows sub-5% Monopar Therapeutics (MNPR) stake in 13G/A - Stock Titan
Monopar Therapeutics stock price target raised to $133 by BTIG - Investing.com Canada
MNPR Maintained by BTIG -- Price Target Raised to $133 - GuruFocus
BTIG Research Forecasts Strong Price Appreciation for Monopar Therapeutics (NASDAQ:MNPR) Stock - marketbeat.com
Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Misses Expectations By $0.13 EPS - MarketBeat
Adage Capital discloses 4.76% Monopar Therapeutics (MNPR) stake including warrants - Stock Titan
Form 8K Monopar Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Monopar Therapeutics' Q2 Net Loss Widens - marketscreener.com
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update on ALXN1840 NDA Submission - Quiver Quantitative
Monopar Reports Q2 2026 Net Loss of $5.3 Million - Quiver Quantitative
Monopar Therapeutics reports Q2 2026: $5.3M net loss, $134.3M cash on hand - TradingView
Monopar Therapeutics 2Q 2026: Net income $(5.31M), EPS $(0.62) — 10-Q Summary - TradingView
Monopar Therapeutics (MNPR) deepens R&D spend but retains $134M cash runway - Stock Titan
Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen - MarketBeat
Monopar Therapeutics Inc. expected to post a loss of 62 cents a shareEarnings Preview - TradingView
Bank of New York Mellon Corp Has $4.31 Million Position in Monopar Therapeutics Inc. $MNPR - marketbeat.com
Why is Monopar Therapeutics stock up today? Resistance levels in focus - Traders Union
Monopar Therapeutics (NASDAQ:MNPR) Sets New 1-Year HighWhat's Next? - marketbeat.com
MNPR Q2'26 Earnings: EPS estimate is (0.66) USD - TradingView
Monopar Therapeutics stock approaches $125.77 resistance as bullish momentum drives gains - Traders Union
Monopar Therapeutics (MNPR) Projected to Post Earnings on Tuesday - MarketBeat
Monopar Therapeutics stock closes near session high as buyers regain control - tradersunion.com
Why is Monopar Therapeutics stock down today? Key support levels to watch - Traders Union
Monopar Therapeutics (NASDAQ:MNPR) Reaches New 52-Week HighWhat's Next? - MarketBeat
MNPR Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Monopar Therapeutics (MNPR) Slips Slightly as Biotech Sector Faces Profit-TakingETF NAV Deviation - dars.gov.et
Monopar Therapeutics Inc (MNPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Monopar Therapeutics Inc (MNPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Monopar Therapeutics Inc (MNPR) Institutional Confidence - TradingKey
Monopar Therapeutics Inc (MNPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Monopar Therapeutics Inc (MNPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MNPR|Monopar Therapeutics Inc|Price:110.450|Chg%:+0.580 - TradingKey
Monopar Therapeutics Inc (MNPR) Cash Flow - TradingKey
BTIG’s Mukherjee Initiates Buy on Monopar Therapeutics, Citing Emerging Head & Neck Cancer Data and Favorable Risk‑Reward Setup - TipRanks
MONOPAR THERAPEUTICS INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $125 FROM $105 - webull.com
Walleye Capital LLC Takes Position in Monopar Therapeutics Inc. $MNPR - marketbeat.com
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monopar Therapeutics Inc Stock (MNPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Vu Quan Anh | Chief Financial Officer |
Dec 26 '25 |
Buy |
69.95 |
1,500 |
104,925 |
1,500 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):